It was observed that the pretreatment with L-TH (120nM/4h) significantly decreased the elevated cADPR and the much consumption of CD38 substrate (NAD+) as compared with CIS-treated cells; the effect that comparable with the potent PARP inhibitor 5-AIQ pretreatment (Fig 7A and 7B). The gene discussed is CD38; the disease is in situ carcinoma.